Valsts: Lielbritānija
Valoda: angļu
Klimata pārmaiņas: VMD (Veterinary Medicines Directorate)
Ramipril
Intervet UK Ltd
QC09AA05
Ramipril
Expired
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vasotop 0.625 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each tablet contains Ramipril 0.625 mg For full list of excipients see section 6.1 3. PHARMACEUTICAL FORM Tablet. Orange oblong flavoured tablets half scored on both sides, with embossing of ‘V’ on both sides of score line. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of congestive heart failure (NYHA: decompensation grades II-IV). The product can be used in combination with diuretics, and the cardiac glycosides digoxin or methyl-digoxin. 4.3 CONTRAINDICATIONS Not to be used in haemodynamically relevant vascular stenosis (e.g. aortic stenosis) or obstructive hypertrophic cardiomyopathy. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES The use of ACE inhibitors in dogs with hypovolaemia/dehydration (e.g. due to large doses of a diuretic, vomiting or diarrhoea) can lead to acute hypotension. In such cases the fluid and electrolyte status should first be balanced and treatment suspended until it is stabilised. This also applies if clinical signs of apathy or ataxia occur during treatment with the product (potential signs of hypotension). After these symptoms have subsided, the treatment should be continued at 50% of the original dose. Substances that deplete blood volume, such as diuretics, or which vasodilate, such as angiotensin-converting enzyme (ACE) inhibitors, may contribute to lowering systemic blood pressure. This may result in pre-renal uraemia (azotaemia). Renal function should be monitore Izlasiet visu dokumentu